Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYC140 in Advanced Leukemias or Myelodysplastic Syndromes
NCT03884829Phase 1Terminated
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Mar 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of plogosertib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and 2 more, sponsored by Cyclacel Pharmaceuticals, Inc. Primary endpoint: Number of Patients who experience dose-limiting toxicity. Started Mar 2019; status: terminated.
02
Drugs
plogosertib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03884829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03884829.